The Readout Loud
Episode 192: Michael Gilman on the future of RNA drugs, plus #JPM22 in review and more Biogen news
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
First, STAT health tech correspondent Katie Palmer joins us to recap the J.P. Morgan Healthcare Conference. Then, we discuss the latest twist in Biogen's quest to expand the use of Aduhelm and what it means for the treatment of Alzheimer's disease. Finally, Arrakis Therapeutics CEO Michael Gilman calls in to explain how targeting RNA can treat disease and why the characters in "Dune" don't just shoot each other with laser guns.